Research Article

Gene Expression Profile Analysis of T1 and T2 Breast Cancer Reveals Different Activation Pathways

Margit L. H. Riis, 1,2 Xi Zhao, 3 Fateme Kaveh, 4 Hilde S. Volland, 2,5 Anne-Jorunn Nesbakken, 6 Hiroko K. Solvang, 4 Torben Lüders, 2,5 Ida R. K. Bukholm, 1,2,7 and Vessela N. Kristensen 2,4,5

1 Department of Surgery, Akershus University Hospital, 1478 Lørenskog, Norway
2 Institute for Clinical Medicine, Faculty of Medicine, University of Oslo, 0318 Oslo, Norway
3 Department of Radiology, School of Medicine, Stanford Center for Cancer Systems Biology, Stanford University, Stanford, CA 94305-5488, USA
4 Department of Genetics, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, 0310 Oslo, Norway
5 Department of Clinical Molecular Biology and Laboratory Sciences (EpiGen), Akershus University Hospital, 1478 Lørenskog, Norway
6 Department of Pathology, Akershus University Hospital, 1478 Lørenskog, Norway
7 Institute of Health Promotion, Akershus University Hospital, 1478 Lørenskog, Norway

Correspondence should be addressed to Ida R. K. Bukholm; i.r.k.bukholm@medisin.uio.no

Received 29 November 2012; Accepted 8 January 2013

Breast cancers today are of predominantly T1 (0.1 ≥ 2.0 cm) or T2 (> 2 ≤ 5 cm) categories due to early diagnosis. Molecular profiling using microarrays has led to the notion of breast cancer as a heterogeneous disease both clinically and molecularly. Given the prognostic power and clinical use of tumor size, the purpose of this study was to search for molecular signatures characterizing clinical T1 and T2. In total 46 samples were included in the discovery dataset. After adjusting for hormone receptor status, lymph node status, grade, and tumor subclass 441 genes were differently expressed between T1 and T2 tumors. Focal adhesion and extracellular matrix receptor interaction were upregulated in the smaller tumors while p38MAPK signaling and immune-related pathways were more dominant in the larger tumors. The T-size signature was then tested on a validation set of 947 breast tumor samples. Using the T-size expression signatures instead of tumor size lead to a significant difference in risk for distant metastases (P < 0.001). If further confirmed, this molecular signature can be used to select patients with tumor category T1 who may need more aggressive treatment and patients with tumor category T2 who may have less benefit from it.

1. Introduction

Breast cancer is by far the most frequent cancer among women, and ranks second overall [1]. Guidelines for breast cancer treatment are based upon classical clinicopathological parameters: age, tumor size, grade, lymph node status, and histological type; in addition to hormone receptor status [2]. Lymph node (N) status is the most powerful single indicator of breast cancer prognosis [3], while tumor size, categorized into four groups (T1–4) is the second strongest indicator and is independent of lymph node status [3]. Here we attempted to identify the molecular background behind this prognostic effect of tumor size.

Mammographic screening has led to breast cancer diagnosis at preclinical stage and, as a consequence, most diagnosed cases present as T1 or T2, with significantly better survival in T1 tumors [4]. Nevertheless, T1 tumors may also give recurrence or metastases. Chemotherapy and hormonal treatment reduce the risk of recurrence or distant metastases by approximately 30% and according to the current guidelines whether a tumor is T1 or T2 is a critical factor in treatment decision. However, 70–80% of patients would have survived without adjuvant treatment [5]. How to distinguish the patients that would benefit from adjuvant treatment would therefore be of great value to the patient preventing...
possible severe side effects, and to the community saving from unnecessary health expenses.

Microarray technology has enabled to study thousands of genes simultaneously. Interpretation of the data requires advanced statistical analysis [6] and there has been a long way to clinical implication [7]. Hierarchical clustering has been the simplest algorithm applied to organize both genes and samples into groups based on similarity of gene expression [8]. Based on this, breast cancers have been separated into several molecular subclasses [9]. This implies breast cancer as a heterogeneous group of malignancy with distinct molecular signature. The molecular subgroups have been studied in respect of clinical implication and are significantly correlated to overall survival and recurrence of disease [10]. As opposed to this unsupervised approach, the principle of supervised analysis is one where predictive models are built based on existing knowledge of the clinical characteristics [11, 12]. This methodology has also been used to establish a good and a poor prognosis profile which is a more powerful predictor of outcome in young patients with breast cancer than the standards systems based on clinicohistological criteria [10, 13].

Since one of the most crucial factors of treatment decision is tumor size, we aimed to find a gene expression profile which will best characterize the two most common groups of
tumors: T1 and T2. We first identified the most differentially expressed genes between T1 and T2 tumors in 46 patients and characterized the biological pathways active in each category. We then validated this gene list on other publically available datasets.

2. Materials and Methods

2.1. Sample Collection. Core needle biopsies were collected at Akershus University Hospital, Norway, between 2003 and 2007. The tumors were detected clinically or through screening by mammography. The samples were taken under ultrasound guidance and immediately placed into RNA later (SigmaAldrich, St.Louis, MO, USA). The stabilized samples were stored at −80°C. The study is approved by the Regional Committee for Medical and Health Research Ethics (REK) and all women included have signed a consent form.

This study includes in total 46 samples, 27 T1 and 19 T2 infiltrating ductal carcinomas. T1 lesion is defined as no more than 2 cm in size while T2 lesion is defined as above 2 cm up to 5 cm. The clinical parameters of the tumors are summarized in Table 1 and Figure 1. Within the T1 group two women had recurrence or metastasis, both of these are deceased. In addition two other women in this group are deceased but without cancer specific death. In the T2 group two patients had metastasis or recurrence, one of these has deceased. In addition there was one more case of mortality in this group; this patient developed malignant melanoma with liver metastasis which was the probable cause of death. Among the women in the T2 group two patients developed a new breast cancer.

2.2. RNA Isolation. Frozen biopsies were homogenized in 600 μL Trizol (Invitrogen, Carlsbad, CA, USA) using a 5 mm steel bead (Qiagen, Hilden, Germany) and a Mixer Mill MM301 (Retsch, Haan, Germany) at 20 Hz for 2 min before adding an additional 600μL Trizol, followed by 240 μL chloroform (Sigma Aldrich). After centrifugation (15 min, 12000 × g, 4°C) the upper aqueous phase was transferred to a new tube and RNA precipitated by adding an equal volume of isopropanol. After centrifugation the pellet was washed 2-3 times with 75% ethanol and dissolved in 40 μL RNase-free water (Ambion, Austin, TX, USA). Concentration was measured using NanoDrop (Thermo Fisher Scientific, Waltham, MA, USA) and RNA quality assayed on a 2100 Bioanalyzer (Agilent, Santa Clara, CA, USA). The purified RNA was stored at −80°C.

2.3. Microarray Analysis. 10μg total RNA was amplified using Amino Allyl MessageAmp II aRNA Amplification Kit (Ambion) followed by posttranscriptional labeling with CyDye Cy3 or Cy5 (GE HealthCare, Chalfont St. Giles, UK). As a reference probe universal human reference RNA (UHR; Stratagene, La Jolla, CA, USA) was amplified and labeled as above. Amplification and labeling efficiency were controlled on the NanoDrop. Labeled cRNA corresponding to 20 picomoles cyanine dye each of experimental and reference samples were mixed and hybridized to Agilent

Figure 2: Focal adhesion is one of the pathways upregulated in clinical T1 and downregulated in clinical T2. Red star implies the gene is upregulated in clinical T1 and downregulated in clinical T2.
Whole Human Genome Oligo Microarrays (1 × 44 k format) per manufacturer’s protocol (Ver. 4.1). After hybridization at 60°C for 17 hours the arrays were washed and scanned using an Agilent scanner.

Data collection and quality assessment were performed using Agilent Feature Extraction software v8.5 with default parameters. Preprocessing was performed using JExpress Pro v2.7 [14]. Poor spots flagged by Feature Extraction were filtered out and Loewess normalization applied. Missing values were calculated with the LSimpute function for genes with less than 5% missing values. To find significant changes of genes/probes between the two tumor stages, Statistical Analysis of Microarray (SAM) [15] was applied. To adjust for lymph node status, differential grade, estrogen and progesterone receptor status, and breast cancer subtype, a partial least squares regression analysis was performed with the pls package in R [16, 17]. To find biological functions pathway analysis was performed for the up- and downregulated genes in T1 and T2 using DAVID [18, 19]. The upregulated genes in T1 are simultaneously the downregulated genes in T2 and vice versa. To confirm and visualize the differential expression between T1 and T2 tumors, unsupervised hierarchical clustering using the genes/probes significantly deregulated by SAM was performed in JExpress Pro. The microarray data have been submitted to the ArrayExpress Archive (http://www.ebi.ac.uk/microarray-as/ae/), accession number: E-MTAB-1049.

2.4. Validation Set. To validate the T-size signature in an independent dataset, we collected expression profiles of 947 breast tumor samples [20] from six published microarray datasets [21–26] with updated followups. The datasets are accessible from NCBI’s Gene Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo/) with the following identifiers; GSE6532 for the Loi dataset [21], GSE43494 for the Miller dataset [22], GSE4156 for the Pawitan dataset [23], GSE7390 for the Desmedt dataset [24], and GSE2603 for
2.5. Gene Signatures Evaluated on the Validation Set. For the T-size signature, tumors in the validation set were assigned to either T1-like group or T2-like group using the nearest of the T-size expression centroids (distances computed using correlation to the centroids). The risk group assignment corresponded to the label of the centroid with the highest correlation. We did not apply a correlation cutoff when assigning risk groups; every sample received a classification based on the T-size signature.

We further compared the prognostic power of the T-size signature with eight established prognostic gene signatures for breast cancer. These are Intrinsic [9, 29, 30], PAM50 [31], 70-gene or MammaPrint (Agenda, Amsterdam, The Netherlands) [13, 32], 76-gene [33], Genomic-Grade-Index (GGI) [21, 34], 21-gene-Recurrence-Score (RS) or Oncotype DX (Genomic Health Inc., Redwood City, CA) [35], Wound-Response (WR) signature [36, 37], and Hypoxia signature [38, 39]. All included gene signatures were implemented using the original algorithms. For Intrinsic and PAM50, in addition to subtype classification, a risk score per sample was computed by linear combination of the centroid correlations in ROR-S model (Risk-Of-Relapse scores by Subtype alone) [31]. A pseudo Oncotype DX Recurrence Score per patient was computed by the unscaled Recurrence Score [35]. For 76-genes, GGI and RS, rather than assigning risk groups based on published cutoffs, we used a population-based approach.

Figure 4: Neurotrophin signaling pathway is among the pathways downregulated in clinical T1 and upregulated in clinical T2. Red stars imply genes that are downregulated in clinical T1 and upregulated in T2.
Figure 5: T-size signature for prediction for Distant Metastasis Free Survival (DMFS) on the Affy947 breast cancer dataset. Survival probabilities associated with the risk groups are shown by Kaplan Meier plot. A total of 912 patients had available DMFS status. Follow-up time is shown in month. (a) T-size signature in the complete set. (b) In pT1 tumor subset. (c) In pT2 tumor subset.

2.6. Survival Analysis. The signatures were evaluated for prediction of Distant Metastasis Free Survival (DMFS). A total of 912 patients on the validation set (n = 947) had available DMFS status with median followup for 81 months. The Kaplan-Meier survival curves were plotted for the corresponding risk groups. The differences in survival probabilities associated with the risk groups were tested by a logrank test.

A likelihood ratio test was used to assess the significance of the overall effect in a univariate comparison of predictors. Deviance was used to check the goodness of the model fit. The marginal contribution by a single predictor in the univariate setting was evaluated using the proportion of
Table 1: Summary of patient characteristics.

| Sample | Stage | Size/cm | Grade | Node | ER     | PgR | Recurrence/metastasis | Deceased |
|--------|-------|---------|-------|------|--------|-----|-----------------------|----------|
| 24     | T1    | 0.8     | 2     | 1    | Positive |     | Positive              |          |
| 29     | T1    | 0.8     | 2     | 0    | Positive |     | Positive              |          |
| 51     | T1    | 1.0     | 1     | 0    | Positive |     | Negative              |          |
| 55     | T1    | 0.8     | 3     | 0    | Positive |     | Positive              |          |
| 62     | T2    | 2.5     | 3     | 2    | Negative |     | Negative              |          |
| 69     | T1    | 1.4     | 2     | 0    | Positive |     | Positive              |          |
| 73     | T1    | 1.8     | 2     | 0    | Positive |     | Positive              |          |
| 78     | T1    | 1.2     | 2     | 0    | Positive |     | Positive              |          |
| 81     | T2    | 2.3     | 2     | 1    | Positive |     | Positive              |          |
| 83     | T1    | 1.9     | 3     | 1    | Positive |     | Positive              |          |
| 84     | T1    | 1.0     | 2     | 0    | Positive |     | Positive              |          |
| 94     | T1    | 1.9     | 3     | 0    | Positive |     | Negative              | Yes      |
| 99     | T2    | 4.0     | 3     | 0    | Negative |     | Negative              | Yes      |
| 101    | T1    | 1.9     | 3     | 0    | Positive |     | Positive              | Yes      |
| 122    | T2    | 3.4     | 3     | 1    | Positive |     | Negative              | Yes      |
| 124    | T1    | 0.9     | 1     | 0    | Positive |     | Positive              |          |
| 129    | T1    | 0.8     | 2     | 0    | Positive |     | Negative              |          |
| 130    | T2    | 2.2     | 3     | 2    | Positive |     | Positive              | Yes      |
| 143    | T2    | 2.8     | 2     | 0    | Positive |     | Positive              |          |
| 147    | T1    | 1.0     | 1     | 0    | Positive |     | Positive              |          |
| 148    | T1    | 0.9     | 2     | 0    | Positive |     | Positive              |          |
| 149    | T1    | 1.0     | 1     | 0    | Positive |     | Positive              |          |
| 152    | T1    | 1.5     | 2     | 1    | Positive |     | Positive              |          |
| 170    | T2    | 4.0     | 2     | 1    | Negative |     | Negative              |          |
| 172    | T1    | 1.9     | 2     | 1    | Negative |     | Negative              | Yes      |
| 175    | T2    | 2.5     | 3     | 0    | Negative |     | Negative              |          |
| 176    | T2    | 2.7     | 3     | 0    | Positive |     | Positive              |          |
| 178    | T1    | 1.2     | 2     | 1    | Negative |     | Positive              | Yes      |
| 179    | T1    | 1.8     | 2     | 1    | Positive |     | Positive              | Yes      |
| 191    | T1    | 1.4     | 1     | 0    | Positive |     | Positive              |          |
| 200    | T1    | 1.5     | 2     | 0    | Negative |     | Negative              |          |
| 211    | T1    | 1.7     | 2     | 2    | Positive |     | Positive              |          |
| 213    | T2    | 3.0     | 3     | 1    | Negative |     | Negative              |          |
| 214    | T1    | 1.2     | 2     | 0    | Positive |     | Negative              |          |
| 218    | T2    | 2.1     | 1-2   | 1    | Positive |     | Negative              |          |
| 222    | T2    | 2.1     | 2     | 0    | Positive |     | Positive              | New BC   |
| 227    | T1    | 1.8     | 2     | 0    | Negative |     | Positive              |          |
| 228    | T2    | 3.0     | 3     | 0    | Negative |     | Negative              |          |
| 231    | T2    | 2.1     | 2     | 0    | Positive |     | Negative              |          |
| 233    | T2    | 3.0     | 3     | 0    | Negative |     | Negative              | New BC   |
| 237    | T2    | 2.1     | 2     | 0    | Positive |     | Positive              |          |
| 244    | T1    | 0.6     | 2     | 0    | Positive |     | Positive              |          |
| 270    | T2    | 3.0     | 3     | 0    | Positive |     | Negative              | Yes      |
| 272    | T2    | 2.3     | 2     | 1    | Positive |     | Negative              |          |
| 280    | T2    | 3.2     | 2     | 0    | Negative |     | Positive              |          |
| 283    | T1    | 1.3     | 2     | 1    | Positive |     | Negative              |          |
Table 2: Upregulated pathways in T1 breast cancer tumors compared to T2 tumors.

| Term | Genes | Count | % | P value | Benjamini |
|------|-------|-------|---|---------|-----------|
| Focal adhesion (KEGG_PATHWAY) | MYL7, ITGA2, ITGB3, COL4A6, SHC4 | 5 | 3.5 | 3.6E−2 | 8.6E−1 |
| Arrhythmic right ventricular cardiomyopathy (ARVC) (KEGG_PATHWAY) | LEF1, ITGA2, ITGB3 | 3 | 2.1 | 8.2E−2 | 9.0E−1 |
| Small cell lung cancer (KEGG_PATHWAY) | ITGA2, ITGB3, COL4A6 | 3 | 2.1 | 9.7E−2 | 8.4E−1 |
| ECM-receptor interaction (KEGG_PATHWAY) | CDKN1B, ITGA2, COL4A6 | 3 | 2.1 | 9.7E−2 | 8.4E−1 |

Table 3: Downregulated pathways in T1 breast cancer tumors compared to T2 tumors.

| Term | Genes | Count | % | P value | Benjamini |
|------|-------|-------|---|---------|-----------|
| Neurotrophin signaling pathway (KEGG_PATHWAY) | YWHAZ, GRB2, RAC1, YWHAQ, FR52 | 5 | 2.8 | 4.2E−2 | 9.8E−1 |
| p38 MAPK Signaling Pathway (BIOCARTA) | GRB2, RAC1, MKNK1 | 3 | 1.7 | 5.0E−2 | 9.8E−1 |
| Prion diseases (KEGG_PATHWAY) | CIQA, CIQB, CIQC | 3 | 1.7 | 5.3E−2 | 9.1E−1 |
| Jak-STAT signaling pathway (KEGG_PATHWAY) | OSM, IFNA2, GRB2, IL10RA, IL4R | 5 | 2.8 | 8.1E−2 | 9.2E−1 |
| Systemic lupus erythematosus (KEGG_PATHWAY) | CIQA, CIQB, HLA-DPB1, CIQC | 4 | 2.2 | 8.7E−2 | 8.7E−1 |
| Toll-like receptor signaling pathway (KEGG_PATHWAY) | IFNA2, MYD88, TICAM1, RAC1 | 4 | 2.2 | 9.1E−2 | 8.2E−1 |

variation explained in the outcome variable (PVE) [40], which is an indicator for the importance of covariates in the Cox model. The Hazard Ratio (HR) was used as an accuracy measure for the risk group prediction for different predictors. The concordance index (C-index) [41] was computed to assess the predictive discrimination ability of each of the predictors in the corresponding univariate Cox model. For a multivariate comparison of predictors, the relative importance of a covariate in a multivariate Cox model was measured by the partial PVE.

3. Results

After preprocessing 36,669 genes were included for further analyses. Comparing the gene expression profiles between T1 and T2 tumors and using partial least squares regression (PLS) analysis to adjust for lymph node status, differential grade, hormone receptor status, and breast cancer subtype, yielded 441 genes differentially expressed genes at FDR <1% (Supplementary Table S1 available online at http://dx.doi.org/10.1155/2013/924971). Unsupervised hierarchical clustering using these 441 probes resulted in T1 and T2 tumors to cluster for most part separately (Figure 1) except four T1 tumors that clustered with the T2 tumors. One of these patients developed metastasis to the lung and to the bone, and later died. Another one is still alive but had bilateral breast cancer in addition to primary lung cancer. The last two patients in this group are free of recurrence and metastasis.

3.1. Pathway Analysis. To further study the differences in genes between T1 and T2 tumors, we performed pathway analysis. Of the 441 significant probes, 184 probes were upregulated in T1 (downregulated in T2), and 257 probes were downregulated in T1 (upregulated T2). The genes upregulated in T1 were enriched for several pathways (Table 2), including Focal Adhesion (Figure 2) and ECM-receptor interaction (Figure 3). Among the important upregulated genes are several collagens and integrins, and p27 (cyclin dependent kinase inhibitor 1B).

The downregulated genes in T1, upregulated in T2 were enriched for important pathways like Neurotrophin signaling pathway (Figure 4), p38MAPK signaling pathway, and several pathways involved in immune response (Table 3). Important genes in these pathways are MNK1 (MAP kinase interacting serine/threonine-protein kinase 1), GRB2 (Growth factor receptor bound protein 2), RAC1 (ras-related C3 botulinum toxin substrate 1), and several immune-related genes, such as IFN, IL6, MHCII, and complement component 1.

3.2. Validation of the T-Size Signature. In the validation of the T-size signature, a total of 480 samples were called as T1-like, and 467 were classified as T2-like. For all signatures except Hypoxia on the complete set for DMFS (n = 912), differences in DMFS between risk groups were highly significant (not shown; see Zhao et al. [20]). Specifically for the T-size signature, the separation between T1-like group and T2-like group was highly significant (P < 0.001; Figure 5(a)) with T2-like group associated with higher risk for distant metastasis. We also observed highly significant separation of two risk groups for DMFS in the patient group with pT1 size tumors (n = 440; P < 0.001; Figure 5(b)); while in the pT2 tumor subgroup (n = 459), T-size signature achieved less significant separation for the risk prediction (P = 0.031; Figure 5(c)).

We performed univariate analysis for the T-size signature and clinical parameters including tumor size (1–3), node status (positive versus negative), ER status (positive versus negative), and histological grade (1–3), respectively. The performance comparisons by using the likelihood ratio test, the deviance, the proportion of variation explained (PVE), the concordance index (C-index), and the Hazard Ratio (HR) are summarized in Table 4. A multivariate Cox model was used to simultaneously assess the T-size signature and the included clinical parameters in the study. Due to the known association
Table 4: Univariate comparison of predictors.

| Covariate                  | HR [95% CI]         | P     | PVE     | Deviance | C    |
|----------------------------|---------------------|-------|---------|----------|------|
| T-size signature           |                     |       |         |          |      |
| (Overall effect)           |                     |       |         |          |      |
| T2-like (versus T1-like)   | 1.92 [1.48–2.48]    | 7.22E–07 | 2.76E−02 | 25.55    | 0.58 |
| Tumor size                 |                     |       |         |          |      |
| (Overall effect)           |                     |       |         |          |      |
| 2 (versus 1)               | 1.95 [1.50–2.55]    | 7.83E–07 | 3.62E−02 | 33.38    | 0.60 |
| 3 (versus 1)               | 3.39 [1.96–5.88]    | 1.37E–05 |          |          |      |
| Node                       |                     |       |         |          |      |
| (Overall effect)           |                     |       |         |          |      |
| + (versus –)               | 1.89 [1.46–2.45]    | 1.35E–06 | 2.46E−02 | 22.24    | 0.58 |
| ER                         |                     |       |         |          |      |
| (Overall effect)           |                     |       |         |          |      |
| + (versus –)               | 0.72 [0.55–0.94]    | 1.78E–02 | 5.85E−03 | 5.35     | 0.54 |
| Histological grade         |                     |       |         |          |      |
| (Overall effect)           |                     |       |         |          |      |
| 2 (versus 1)               | 1.78 [1.15–2.77]    | 1.04E–02 | 2.45E−04 | 16.63    | 0.60 |
| 3 (versus 1)               | 2.37 [1.52–3.69]    | 1.78E–02 |          |          |      |

Table 5: Multivariate comparison of predictors.

| Covariate                  | HR [95% CI]         | P     | Partial PVE |
|----------------------------|---------------------|-------|-------------|
| T-size signature           |                     |       |             |
| T2-like (versus T1-like)   | 1.70 [1.25–2.32]    | 8.03E–04 | 1.42E–02    |
| Tumor size                 |                     |       |             |
| 2 (versus 1)               | 1.74 [1.29–2.35]    | 2.72E–04 | 1.62E–02    |
| 3 (versus 1)               | 2.07 [0.97–4.40]    | 5.98E–02 | 1.62E–02    |
| Node                       |                     |       |             |
| + (versus –)               | 1.68 [1.24–2.28]    | 8.11E–04 | 1.25E–02    |
| Histological grade         |                     |       |             |
| 2 (versus 1)               | 1.45 [0.92–2.29]    | 1.14E–01 | 2.05E–02    |
| 3 (versus 1)               | 1.49 [0.91–2.47]    | 1.16E–01 | 2.05E–02    |

between ER status and survival, we included ER status as stratification variable (Table 5).

4. Discussion

Approximately 15% of all women diagnosed with breast cancer die from their disease within 5 years of diagnosis [42] despite having been treated according to national clinical guidelines [2]. Both genomic and clinical variables should be included in a common algorithm to yield the most accurate prediction model. Microarray has made it possible to study thousands of genes simultaneously. This generates information about gene expression profiles that can be computed in different ways. One of these is the clustering of patients according to the gene expression in their tumors. The majority of the gene lists are generated to distinguish patients from being subject to unnecessary adjuvant treatment or with the intention of individualizing therapy and treatment.

Several genetic signatures have been presented [13, 23, 32–34]. This work has led to the development of special kits such as MammaPrint (Agendia, Amsterdam, The Netherlands) [13, 32] and Oncotype DX (Genomic Health Inc., Redwood City, CA, USA) [35]. By combining information from multiple gene signatures, one would potentially increase the prediction power and bring out an overall picture of this disease. Zhao et al. aimed to develop an analytical framework that allows us to utilize the combined strength from individual gene signatures [43]. Such a framework and the resulting model will be broadly applicable for survival prediction across heterogeneous tumor groups capturing a broad spectrum of biological aspects. The tumor size associated signature presented here has the purpose to identify the molecular characteristics associated to size and does not claim to provide prognostic index superior to the existing ones. The signature specific difference in DMFS within the T1 subgroup and the T2 subgroup, shown here, are used only to suggest that it can be used as supplementary information to tumor size.

Most first generation signatures are good for predicting prognosis in early stage breast cancer. There is only a minor overlap in genes in the different signatures [44], but they produce similar risk group assignment in the same dataset.
Proliferation and the level of proliferation-related genes are the strongest prognostic factors in ER positive cancer. Proliferation-related genes are often highly expressed in ER negative cancers, so in the first generation signatures almost all ER negative cancers seem to have poor prognosis. It was initially meant that these prognostic signatures could replace the classical histopathological findings, but meta-analysis has revealed that tumor size and lymph node status give prognostic information independent of the molecular signatures [45].

The present study attempts to identify, independent of grade, receptor status and lymph node status, the molecular signature, and the underlying biological pathways associated to tumor size, which is an objective property without possibility of interobserver disagreement. The most significant pathways upregulated in T1 compared to T2 are focal adhesion, ECM-receptor interaction, and two organ specific pathways (Table 2). Important genes occur at several steps in these pathways. One of these genes being P27(Kip) (cyclin dependent kinase inhibitor 1B). The cell-cycle regulating protein p27\(^{Kip1}\) (p27) has dual roles by acting as both a cdk inhibitor and as an assembly factor for different cdk complexes. Loss of p27 has been linked to malignant features in different tumors [46]. High levels of p27 are expressed in normal human mammary epithelium, but loss of p27 is frequent in breast cancer and has been demonstrated to have prognostic implications [47]. Patients with tumors expressing low levels of p27 were associated with poor prognosis, and it is especially pronounced in hormone-receptor positive tumors [48]. HER2 positive primary breast cancers often reveal low levels of p27 [49]. As mentioned, in our material p27 is upregulated in T1 tumors compared to T2 tumors and this is in coherence with earlier studies. Thus this could be a possible marker, among others, that could be used to select the T1 tumors that have a greater possibility of recurrence. The lower p27, the worse prognosis, consequently requiring stronger treatment.

Pathways downregulated in T1 and upregulated in T2 are shown in Table 3. These are all pathways associated with the immune response, and a majority of the actual downregulated genes are immune response related genes, like IFN, IL6, MHC II, and Complement component 1. This is consistent with a more aggressive lesion that requires more effort from the immune system. Among the genes downregulated in T1 tumors compared to T2 tumors is GRB2. Grb2 is an adaptor protein that is essential for a variety of cellular functions and acts as a critical downstream intermediary in several oncogenic signaling pathways [50]. In human breast cancer cells Grb2 is overexpressed. In an unpublished work we have demonstrated that there is a significant difference in the expression of this gene in normal tissue and breast cancer tissue, and also in normal tissue adjacent to tumor. The role of Grb2 as a signal transducer for several oncogenic growth factor receptors and the broad involvement of Grb2 in multiple steps of the metastasis cascade make it a good target for antitumor therapeutic strategies [50]. Like for p27, maybe this gene could be measured in the patients with smaller tumors to select those with worse prognosis.

RAC1 (ras-related C3 botulinum toxin substrate 1) may represent an attractive target. Rac GT-Pases, small G-proteins widely implicated in tumorigenesis and metastasis, transduce signals from tyrosine-kinase, G-protein-coupled receptors (GPCRs), and integrins, and control a number of essential cellular functions including motility, adhesion, and proliferation. In breast cancer cells Ral1 is a downstream effector of ErbB receptors and mediates migratory responses by ErbB1/EGFR ligands such as EGF or TGF\(\alpha\) and ErbB3 ligands such as herregulins [51]. This gene is a potential target for use in therapy of breast cancer.

5. Conclusions

In summary we show here that there is a molecular profile that is associated to tumor size. Thus a gene-expression signature-based approach combined with the classical TNM classification as well as analysis of key genes may pave the way to improved individualized therapy.

Conflict of Interests

The authors declare that they have no conflict of interests.

Authors’ Contribution

X. Zhao, F. Kaveh, I. R. K. Bukholm, and V. N. Kristensen contributed equally to the work and should be considered as second authors and cosenior authors, respectively.

Acknowledgments

The authors are grateful to our colleagues at the Department of Radiology and the Department of Surgery, Akershus University Hospital for their help with the specimen collection. They also would like to thank the Department of Pathology for immunohistochemistry help. This work was supported by Grant of the South-Eastern Norway Regional Health Authority (Helse Sør-Ost) no. 2789119 and of the Akershus University Hospital no. 2679030 and no. 2699015 to V. N. Kristensen.

References

[1] J. Ferlay, H. Shin, F. Bray et al., “GLOBOCAN 2008 v1.2, cancer incidence and mortality worldwide,” in IARC CancerBase, 2012, http://globocan.iarc.fr.
[2] A. Goldhirsch, J. H. Glick, R. D. Gelber et al., “Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005;” *Annals of Oncology*, vol. 16, no. 10, pp. 1569–1583, 2005.
[3] S. Ciatto, S. Cecchini, A. Iossa, and G. Grazzini, “‘T’ category and operable breast cancer prognosis,” *Tumori*, vol. 75, no. 1, pp. 18–22, 1989.
[4] A. H. Olsen, S. H. Njor, and E. Lyng, “Estimating the benefits of mammography screening: the impact of study design,” *Epidemiology*, vol. 18, no. 4, pp. 487–492, 2007.
[5] Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), “Effects of chemotherapy and hormonal therapy for early breast
cancer on recurrence and 15-year survival: an overview of the randomised trials,” *The Lancet*, vol. 365, no. 9472, pp. 1687–1717, 2005.

[6] D. B. Allison, X. Cui, G. P. Page, and M. Sabripour, “Microarray data analysis: from disarray to consolidation and consensus,” *Nature Reviews Genetics*, vol. 7, no. 1, pp. 55–65, 2006.

[7] L. D. Miller and E. T. Liu, “Expression genomics in breast cancer research: microarrays at the crossroads of biology and medicine,” *Breast Cancer Research*, vol. 9, no. 2, article 206, 2007.

[8] M. B. Eisen, P. T. Spellman, P. O. Brown, and D. Botstein, “Cluster analysis and display of genome-wide expression patterns,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 95, no. 25, pp. 14863–14868, 1998.

[9] C. M. Perou, T. Sorlie, M. B. Eisen et al., “Molecular portraits of human breast tumours,” *Nature*, vol. 406, no. 6797, pp. 747–752, 2000.

[10] L. J. Van’t Veer, H. Dai, M. J. van de Vijver et al., “Gene expression profiling predicts clinical outcome of breast cancer,” *Nature*, vol. 415, no. 6871, pp. 530–536, 2002.

[11] R. Tibshirani, T. Hastie, B. Narasimhan, and G. Chu, “Diagnosis of multiple cancer types by shrunkcen centroids of gene expression,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 99, no. 10, pp. 6567–6572, 2002.

[12] T. Sorlie, “Molecular portraits of breast cancer: tumour subtypes as distinct disease entities,” *European Journal of Cancer*, vol. 40, no. 18, pp. 2667–2675, 2004.

[13] M. J. van de Vijver, Y. D. He, L. J. van’t Veer et al., “A gene expression signature as a predictor of survival in breast cancer,” *The New England Journal of Medicine*, vol. 347, no. 25, pp. 1999–2009, 2002.

[14] B. Dysvik and I. Jonassen, “J-Express: exploring gene expression data using Java,” *Bioinformatics*, vol. 17, no. 4, pp. 369–370, 2001.

[15] V. G. Tusher, R. Tibshirani, and G. Chu, “Significance analysis of microarrays applied to the ionizing radiation response,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 98, no. 9, pp. 5116–5121, 2001.

[16] B. H. Mevik and R. Wehrens, “The pls package: principal component and partial least squares regression in R,” *Journal of Statistical Software*, vol. 18, no. 2, pp. 1–23, 2007.

[17] R Development Core Team, *R: A Language and Environment for Statistical Computing*, R Foundation for Statistical Computing, Vienna, Austria, 2010.

[18] D. W. Huang, B. T. Sherman, Q. Tan et al., “The DAVID Gene Functional Classification Tool: a novel biological module-centric algorithm to functionally analyze large gene lists,” *Genome Biology*, vol. 8, no. 9, article R13, 2007.

[19] D. W. Huang, B. T. Sherman, and R. A. Lempicki, “Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources,” *Nature Protocols*, vol. 4, no. 1, pp. 44–57, 2009.

[20] X. Zhao, E. A. Rødeland, T. Sorlie, and H. G. Russnes, “Systematic assessment of prognostic gene signatures for breast cancer shows distinct influence of time and ER status,” *under review*.

[21] S. Loi, B. Haibe-Kains, C. Desmedt et al., “Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade,” *Journal of Clinical Oncology*, vol. 25, no. 10, pp. 1239–1246, 2007.

[22] L. D. Miller, J. Smeds, J. George et al., “An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 102, no. 38, pp. 13550–13555, 2005.

[23] Y. Pawitan, B. Bjohle, L. Amler et al., “Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts,” *Breast Cancer Research*, vol. 7, no. 6, pp. R953–R964, 2005.

[24] C. Desmedt, F. Piette, S. Loi et al., “Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series,” *Clinical Cancer Research*, vol. 13, no. 11, pp. 3207–3214, 2007.

[25] A. J. Minn, G. P. Gupta, P. M. Siegel et al., “Genes that mediate breast cancer metastasis to lung,” *Nature*, vol. 436, no. 7050, pp. 518–524, 2005.

[26] K. Chin, S. DeVries, J. Fridlyand et al., “Genomic and transcriptional aberrations linked to breast cancer pathophysiology,” *Cancer Cell*, vol. 10, no. 6, pp. 529–541, 2006.

[27] R. A. Irizarry, B. M. Bolstad, F. Collin, L. M. Cope, B. Hobbs, and T. P. Speed, “Summaries of Affymetrix GeneChip probe level data,” *Nucleic Acids Research*, vol. 31, no. 4, article e15, 2003.

[28] A. H. Sims, G. J. Smethurst, Y. Hey et al., “The removal of multiplicative, systematic bias allows integration of breast cancer gene expression datasets—improving meta-analysis and prediction of prognosis,” *BMC Medical Genomics*, vol. 1, no. 1, article 42, 2008.

[29] C. M. Perou, S. S. Jeffrey, M. van de Rijn et al., “Distinctive gene expression patterns in human mammary epithelial cells and breast cancers,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 96, no. 16, pp. 9212–9217, 1999.

[30] T. Sorlie, C. M. Perou, R. Tibshirani et al., “Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 98, no. 19, pp. 10869–10874, 2001.

[31] P. S. Bernard, J. S. Parker, M. Mullins et al., “Supervised risk predictor of breast cancer based on intrinsic subtypes,” *Journal of Clinical Oncology*, vol. 27, no. 8, pp. 1160–1167, 2009.

[32] M. Buyse, S. Loi, L. van’t Veer et al., “Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer,” *Journal of the National Cancer Institute*, vol. 98, no. 17, pp. 1183–1192, 2006.

[33] Y. Wang, J. G. M. Klijn, Y. Zhang et al., “Gene expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer,” *The Lancet*, vol. 365, no. 9460, pp. 671–679, 2005.

[34] C. Sotiriou, P. Wirapati, S. Loi et al., “Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis,” *Journal of the National Cancer Institute*, vol. 98, no. 4, pp. 262–272, 2006.

[35] S. Paik, S. Shak, G. Tang et al., “A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer,” *The New England Journal of Medicine*, vol. 351, no. 27, pp. 2817–2826, 2004.

[36] H. Y. Chang, D. S. A. Nuyten, J. B. Sneddon et al., “Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 102, no. 10, pp. 3738–3743, 2005.

[37] H. Y. Chang, J. B. Sneddon, A. A. Alizadeh et al., “Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds,” *PLoS Biology*, vol. 2, no. 2, article e7, 2004.

[38] S. T. Chi, Z. Wang, D. S. A. Nuyten et al., “Gene expression programs in response to hypoxia: cell type specificity and
prognostic significance in human cancers,” *PLoS Medicine*, vol. 3, no. 3, article e47, 2006.

[39] D. S. A. Nuyten, T. Hastie, J. T. A. Chi, H. Y. Chang, and M. J. van de Vijver, "Combining biological gene expression signatures in predicting outcome in breast cancer: an alternative to supervised classification," *European Journal of Cancer*, vol. 44, no. 15, pp. 2319–2329, 2008.

[40] M. Schemper, “The relative importance of prognostic factors in studies of survival,” *Statistics in Medicine*, vol. 12, no. 24, pp. 2377–2382, 1993.

[41] F. Harrell, K. Lee, and D. Mark, “Tutorial in biostatistics multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors,” *Statistics in Medicine*, vol. 15, pp. 361–387, 1996.

[42] H. Brenner, "Long-term survival rates of cancer patients achieved by the end of the 20th century: a period analysis," *The Lancet*, vol. 360, no. 9340, pp. 1131–1135, 2002.

[43] X. Zhao, T. Sørlie, B. Naume et al., "Combining gene signatures improves prediction of breast cancer survival," *PLoS ONE*, vol. 6, no. 3, Article ID e17845, 2011.

[44] C. Fan, D. S. Oh, L. Wessels et al., “Concordance among gene-expression-based predictors for breast cancer,” *The New England Journal of Medicine*, vol. 355, no. 6, pp. 560–569, 2006.

[45] P. Wirapati, C. Sotiriou, S. Kunkel et al., “Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures,” *Breast Cancer Research*, vol. 10, no. 4, article R65, 2008.

[46] M. Stendahl, S. Nilsson, C. Wigerup et al., “P27Kip1 is a predictive factor for tamoxifen treatment response but not a prognostic marker in premenopausal breast cancer patients;” *International Journal of Cancer*, vol. 127, no. 12, pp. 2851–2858, 2010.

[47] I. M. Chu, L. Hengst, and J. M. Slingerland, “The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy,” *Nature Reviews Cancer*, vol. 8, no. 4, pp. 253–267, 2008.

[48] P. L. Porter, W. E. Barlow, I. T. Yeh et al., “p27Kip1 and cyclin E expression and breast cancer survival after treatment with adjuvant chemotherapy,” *Journal of the National Cancer Institute*, vol. 98, no. 23, pp. 1723–1731, 2006.

[49] L. Newman, W. Xia, H. Y. Yang et al., “Correlation of p27 protein expression with HER-2/neu expression in breast cancer,” *Molecular Carcinogenesis*, vol. 30, no. 3, pp. 169–175, 2001.

[50] A. Giubellino, T. R. Burke, and D. P. Bottaro, “Grb2 signaling in cell motility and cancer,” *Expert Opinion on Therapeutic Targets*, vol. 12, no. 8, pp. 1021–1033, 2008.

[51] E. Wertheimer, A. Gutierrez-Uzquiza, C. Rosemblit, C. Lopez-Haber, M. S. Sosa, and M. G. Kazanietz, “Rac signaling in breast cancer: a tale of GEFs and GAPs,” *Cellular Signalling*, vol. 24, no. 2, pp. 353–362, 2012.
Submit your manuscripts at http://www.hindawi.com